Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | ASH 2021 highlights in CML

Michael Deininger • 12 Dec 2021
ASH 2021
Chronic Myeloid Leukemia Leukemia

Michael Deininger, MD, PhD, University of Utah, Salt Lake City, UT, shares his highlights from ASH 2021, including data on treatment-free remission and related clinical trial data within the field of chronic myeloid leukemia (CML). Dr Deininger additionally highlights advances made in molecular biology. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Michael Deininger

Ongoing studies in CML: investigating asciminib toxicity and improving TFR rates
1:24
Ongoing studies in CML: investigating asciminib toxicity and improving TFR rates
Michael Deininger • 21 Oct 2022
Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CML
1:09
Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CML
Michael Deininger • 21 Oct 2022
ESH CML workshop highlights: 3D genomics and nuclear organization
1:33
ESH CML workshop highlights: 3D genomics and nuclear organization
Michael Deininger • 21 Oct 2022
Final results of the BFORE trial: bosutinib vs imatinib in CP-CML
1:10
Final results of the BFORE trial: bosutinib vs imatinib in CP-CML
Michael Deininger • 21 Oct 2022

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals